絞り込み

17379

広告

Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials.

著者 Hao C , Tian J , Liu H , Li F , Niu H , Zhu B
Medicine (Baltimore).2017 Jun ; 96(26):e7325.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (68view , 0users)

Full Text Sources

Medical

Anti-PD-1 monoclonal antibodies, nivolumab and pembrolizumab, and anti-CTLA-4 antibody ipilimumab are being in clinic trials to treat melanoma. Here, we performed a meta-analysis to evaluate the efficacy and toxicity of them against advanced melanoma.
PMID: 28658143 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード